Several dozen genetic variants associate with serum urate levels, but the precise molecular mechanisms by which they affect serum urate are unknown. Here we tested for functional linkage of the maximally-associated genetic variant rs1967017 at the PDZK1 locus to elevated PDZK1 expression.
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INTRODUCTION
Hyperuricemia is necessary but not sufficient for gout (1) . Serum urate levels have a considerable heritable component (2, 3) . Therefore understanding the molecular mechanisms of serum urate control will reveal important knowledge on the etiology of gout. Genome-wide association studies (GWAS) in several populations to detect genetic variants controlling serum urate levels have identified several dozen loci (4-7). Most of these loci also associate with gout (4, 8, 9) . The loci of strongest effect include genes encoding renal and gut uric acid transporters (e.g. SLC2A9, ABCG2, SLC22A12) and their accessory molecules (e.g. PDZK1). The well-characterized ABCG2 p.Gln141Lys protein variant is highly likely to be causal (10). However, the causal genes and genetic variants at the considerable majority of the serum urate loci remain unconfirmed (11).
Co-localization analysis of GWAS and expression quantitative trait loci (eQTL) has identified instances where genetic variation correlates with changes in gene expression and this strategy has identified 19 candidate causal genes for serum urate control (7) .
The PDZ (PSD-95, DglA, and ZO-1) domain-containing protein PDZK1 is a binding partner of the canonical uric acid urate transporter 1 (URAT1). PDZK1 also physically interacts, and has co-ordinate expression with, the majority of transporters for uric acid (12) . For example in human kidney samples PDZK1 protein and mRNA levels correlate with a range of apical transporters (13) and PDZK1 has been implicated in regulation of the expression of ABCG2 in human intestinal cell lines (14) . Protein-protein interaction occurs via contact between PDZK1 and a PDZ-interacting domain present at the extreme C-terminal end of the various transporters. This has led to the idea that PDZK1 acts as a scaffold for a uric acid 'transportosome' (15); a function that implicates PDZK1 as a key molecule in urate homeostasis (12) . PDZK1 has the potential to regulate the cellular location of, and/or stabilize, uric acid transporters and co-transport molecules. Therefore the regulation of PDZK1 levels would be expected to contribute to urate homeostasis, making understanding of the molecular mechanisms that control PDZK1 expression important. This is particularly important in the context of reports of association of PDZK1 with gout in multiple ancestral groups (8, 16, 17) and the established role of renal and gut under-excretion of uric acid as a cause of gout (18, 19) . Given that a urate GWAS association signal maps to a small region (<10 kb) immediately upstream of the transcription start site of PDZK1 (4, 20) , our aim was to use in vivo and in vitro approaches to understand if variants in proximity to PDZK1 control serum urate levels by modulating transcription of this gene.
RESULTS

Association with serum urate levels and PDZK1 expression -rs1967017 as a candidate causal variant
We used imputation to update the Kottgen et al. analysis performed in 2012 (4) using the latest reference haplotypes ( figure 1A) . This revealed the maximal region of association to reside in a tightly-defined 1 kb region (145.711 Mb) upstream of the PDZK1 transcription start site. Probabilistic Annotation Integrator (PAINTOR) analysis (21) suggested that of all the associated SNPs, rs1967017 is the most likely to be causal (Zscore 11.2, PAINTOR p = 0.93) ( Table S1 ). The rs1967017 SNP is located 4 kb upstream of the transcription start site of the PDZK1 gene. Analysis of the GTEx database (22) revealed that rs1967017 is a strong eQTL for PDZK1 in colon (p = 1.3 x 10 -11 ) and small intestine (p = 8.3 x 10 -7 ) (figure S1A). rs1967017 is a weaker eQTL for PDZK1 in the pancreas and there was no evidence for an eQTL in the liver or stomach. There are currently no renal eQTL data available in GTEx. However three separate studies provide no evidence for rs1967017 as an eQTL in the kidney (23, 24) or in the glomerulus (25 figure S1B). Co-localisation analysis using COLOC (26) gave a posterior probability of 0.93 for the serum urate GWAS and PDZK1 colon eQTL signals to co-localise ( figure   1B ). The similarity between the signals is also evident from figure 1. Using the tightlyassociated surrogate marker rs1471633 (LD with rs1967017 is r 2 =1 in European),we determined that the urate-increasing allele (A for rs1471633, completely correlated with T for rs1967017) associated with increased expression of PDZK1, with reduced expression requiring two copies of the urate-decreasing allele (C for rs1471633, completely correlated with C for rs1967017) in the colon, with only one copy required in the small intestine (figure S1A).
Using ENCODE (27) , we determined that the region harboring rs1967017 is contained within a transcriptionally-active domain (H3K27ac3, H3K4me1, H3K4me2; figure S2 ).
Analysis of transcription factor binding in multiple cell lines showed that several transcription factor binding sites are present in the region, including those recruiting HNF4A, although HNF4A binding is restricted to the HepG2 cell line. Interestingly, there is a signal of association of serum urate at the HNF4A locus in the Kottgen et al. (4) GWAS ( figure S3 ). Significantly, the urate-raising T allele of rs1967017 that is associated with increased expression of PDZK1 markedly strengthens an existing HNF4A binding site, with the binding score increasing 4-fold (from 2.645 to 8.845) when the T allele is present, compared with the C allele (figure 1C) (28) Together, the data indicate that rs1967017 resides in a region that controls PDZK1 expression and that the T>C variant is likely to affect PDZK1 transcription.
The rs1967017 regulatory region drives gene expression in kidney, liver and intestine
Conservation of key functional genes (such as those involved in urate transport) through evolution enables the use of animal models to clarify spatiotemporal gene expression. We used the zebrafish animal model as a read-out to determine in which tissues the rs1967017 regulatory region might drive gene expression. Human PDZK1 is expressed at the highest level in the kidney, and is also expressed in the liver and intestine (Table 1) .
Zebrafish pdzk1 is expressed in kidney, nephric duct and intestinal bulb at 5 days postfertilization (dpf) (29). The similar expression profiles of the human and fish Pdzk1 orthologs supports the hypothesis that regulatory information driving expression of PDZK1/pdzk1 is conserved. We created stable transgenic zebrafish lines using an 857 bp putative regulatory region containing either allele of rs1967017 (C or T) fused to enhanced green fluorescent protein (eGFP). GFP expression was observed as early as 13-14 hours post-fertilization (hpf; 12-somite stage, data not shown). In 4 days post-fertilization (dpf) transgenic zebrafish embryos, expression driven by the T allele (figure 2A-A'') and the C allele (figure 2B-B") was observed in the glomerulus (red arrows), the nephric ducts (orange arrows) and the intestinal epithelium (yellow arrows). Confocal analysis at 5 dpf confirmed expression in the same locations (figure 2C, D). Expression of eGFP in the rs1967017-C/T-GFP transgenic lines was very similar to the endogenous expression pattern of pdzk1 expression in zebrafish (29), and consistent with the expression of PDZK1 in human (Table 1 ). The expression pattern driven by rs1967017 C allele (urate decreasing in humans) and rs1967017 T allele (urate increasing in humans) was spatiotemporally identical. However, expression driven by the T allele was noticeably less robust in the glomerulus than that driven by the C allele (figure S4), indicating that the T>C base change confers subtle differential activity in zebrafish. To determine more precisely the identity of tissue expression in zebrafish, we sectioned 21-day-old larvae and analyzed GFP mRNA distribution by in situ hybridization. We found intense GFP staining in the liver and in the intestinal epithelium of zebrafish, with less intense staining present in the kidney ( figure 2E ). This distribution reflects the relative levels of HNF4A expression in human tissues from GTEx (Table 1) . GFP expression is also coincident with the previously reported expression of hnf4a in zebrafish kidney, liver and intestine (30, 31) .
The results indicate that the human DNA sequence harboring the rs1967017 SNP has sufficient information to recapitulate the normal expression pattern of PDZK1. Moreover, although information conferring tissue identity was not affected by the variant base in the rs1967017 SNP, the C>T base variation affects quantity and/or stability of expression in zebrafish glomerulus (figure s4). Together, the results suggest it is unlikely that rs1967017 affects serum urate via altered spatiotemporal expression of PDZK1.
The rs1967017 urate-raising T allele increases gene expression in human cells
To determine if the regulatory region containing rs1967017 influences gene expression in human cells, we cloned the 857 bp region (described above) into a plasmid expressing luciferase (pGL4.23). Using a dual luciferase reporter system, we determined that this region acts as an enhancer in two different cell lines, HEK293 (human embryonic kidney) and HepG2 (liver) (figure 3). In HEK293 cells, both alleles (C and T) were able to enhance luciferase expression ( figure 3A ). In HepG2 liver cells, the urate-decreasing C allele caused a small but non-significant increase in expression. In contrast, the urateincreasing T allele was highly active in HepG2 liver cells, conferring ~6-fold more luciferase expression than it did in HEK293 cells ( figure 3B ). In both cell lines, the T allele was more active than the C allele, with activity increased over the C allele by ~2fold in HEK293 and ~10-fold in HepG2.
The rs1967017 urate-raising allele is dependent on HNF4A for enhancing transcription in HepG2 cells
We investigated whether the urate-increasing T allele, which strengthens an HNF4A binding site (figure 1), confers increased transcriptional activity mediated by HNF4A expression. Notably, the kidney cell line HEK293 has very low mRNA levels of HNF4A in contrast to HepG2 where it is robustly expressed (figure S5, S6). Because the T allele is a strong enhancer of luciferase expression in HepG2, we were interested to determine if knock-down of HNF4A in HepG2 cells would block the ability of the T allele to increase luciferase transcription (figure 4).
siRNA knockdown of HNF4A in HepG2 cells was effective in reducing HNF4A mRNA (figure 4A) and protein (figures 4B, S6) levels. We also observed down regulation of endogenous PDZK1 mRNA upon depletion of HNF4A ( figure 4C ). Depletion of HNF4A resulted in a ~3-fold reduction in the ability of the T allele to enhance luciferase expression, whereas expression driven by the C allele was not affected by HNF4A reduction (figure 4D, E). Therefore, in HEPG2 cells that express HNF4A, the enhancer activity of the T allele is dependent on maintenance of HNF4A levels.
HNF4A binds to the rs1967017 region in HepG2 cells
To determine if HNF4A directly regulates the rs1967017 enhancer region, we performed a quantitative ChIP assay in HepG2 cells, which are heterozygous for rs1967017 (32).
Following HNF4A immunoprecipitation, a 202 bp fragment was amplified using primers flanking the target HNF4A motif. An ABCC6 promoter region bound by HNF4A (33) was used as positive control, and human β -globin as negative control. Quantitative amplification of HNF4A at the rs1967017 region was approximately double the levels of the ABCC6 positive control, confirming that HNF4A binds the rs1967017 enhancer region ( figure 4F ). To determine if the urate-increasing T allele is bound preferentially to the urate-decreasing C allele, we deep-sequenced the 202 bp immunoprecipitated amplicon containing the target motif in samples before and after HNF4Aimmunoprecipitation. From this experiment, we were not able to conclusively determine a preference of HNF4A for the T allele, although there was a trend for preferential immunoprecipitation of the T allele in one of two replicates (Table S2 ).
DISCUSSION
Many genetic variants that contribute to the risk of complex phenotypes act by influencing expression of genes, rather than by altering their coding sequence (34). Here, we show that one of the maximally associated SNPs at PDZK1 (rs1967017) and most likely to be causal by PAINTOR analysis directly affects PDZK1 expression levels. A DNA segment containing rs1967017 was able to drive gene expression in zebrafish and in two human cell lines. The 857 bp DNA segment had sufficient information to confer kidney, liver and intestine expression in zebrafish, matching the tissue expression profile of PDZK1 in human, suggesting that regulation of this gene is conserved through evolution. Interestingly, we observed expression driven by the rs1967017 enhancer in the epithelial cells of the zebrafish intestine, which is a cell type in which one would expect to find solute transporters. While the identity of the polymorphic variant nucleotide at rs1967017 generally did not affect tissue-specific gene expression in zebrafish, it did modulate the level of expression observed in the kidney, with the urate-increasing T allele conferring weaker expression than the C allele. This is consistent with our understanding of the composite nature of gene regulation and likely reflects the presence of a different complement (or activity) of transcription factors in kidney, compared with gut, available to enhance transcription from the rs1967017 element.
There was a robust and reproducible effect of the variant nucleotide at rs1967017 on level of gene expression in two human cell lines. HEK293 is a cell line frequently used to model human kidney (35) and in this line, the urate-increasing T allele enhanced gene expression comparative to the C allele. However, the T allele was 10-fold more active in the liver cell line HepG2. The reason for this is likely to be that the T variant strengthens a consensus binding sequence for HNF4A, a transcription factor that is expressed in HepG2 but not HEK293. Supporting a causal role for rs1967017, PDKZ1 expression is activated by the nuclear receptor thyroid hormone receptor β (THRB) in HEPG2 cells, with the T allele of rs1967017 associated with increased transactivation by THRB compared to the C allele (24). This is not observed for either allele of rs1471633, the other maximally urate-associated variant at the locus (figure 1). In our data the enhanced reporter expression was substantially reduced when HNF4A was knocked down in HepG2 cells, and was accompanied by down regulation of endogenous PDZK1. Our results are consistent with the report that the zebrafish pdzk1 promoter is bound by hnf4a
and that pdzk1 expression in the zebrafish digestive tract is hnf4a dependent (31).
Furthermore, regulation of PDZK1 by HNF4A is likely to be direct, since HNF4A physically binds the rs1967017 element ( figure 4F ). Although we could only obtain suggestive preliminary evidence that the T allele is bound preferentially bound by HNF4A over the C allele, the eQTLs of rs1967017 with PDZK1 and the fact that variants at HNF4A also associate with serum urate levels give confidence to the hypothesis that HNF4A modulates PDZK1 expression as part of an enhancer complex located within the locus marked by rs1967017.
PDZK1 is a scaffolding protein involved in assembly of a transporter complex in the apical membrane of the proximal tubule of the kidney (12). Given that the urateincreasing T allele at rs1967017 associates with increased expression of PDZK1, it is reasonable to assume that it increases PDZK1 protein levels. The importance of the ratio of PDZK1 to uric acid transport proteins (such as URAT1, encoded by SLC22A12) that it interacts with in the kidney is unknown, but it is established that PDZK1 stabilizes transporter localization in the membrane and increases transporter activity (12, 15) . It was interesting to note that only tissues with very strong evidence for an eQTL were the colon and small intestine, with no evidence for an eQTL in the kidney (23-25). It is possible that other regulatory mechanisms exist in the kidney instead of the rs1967017-mediated regulatory mechanism of PDZK1 expression observed in the gut. For example it has recently been shown that HNF1A positively regulates PDZK1 expression and binds to the PDZK1 promoter in the human kidney (13). In figure 5 , we provide a model for the mechanism of action of the rs1967017 variant that best explains the collective data. We propose that the enhancer variant rs1967017 modulates PDZK1 expression in the intestine (an important site of urate excretion) but not in the kidney. Rs1967017-mediated regulation of expression PDZK1 in intestine would depend on the transcription factor HNF4A, which is highly expressed in intestine and liver relative to kidney (www.gtexportal.org), and which physically binds to the enhancer containing rs1967017.
The T-allele of rs1967017 strengthens the binding site for HNF4A and increases the expression of PDKZ1 in the gut. Increased HNF4A binding leads to increased PDZK1 protein, which is predicted to stabilise the transportosome and increase the activity of uric acid transporters, such as ABCG2 (14, 36) . In human kidney samples there is no association between rs1967017 and PDZK1 expression (23-25). Therefore we propose that HNF1A-dependent regulation of PDZK1 expression independent of rs1967017 is the dominant mechanism in the kidney.
Approximately one-third of the excretion of uric acid occurs via the intestine, with the remainder via the kidney (12). Activity of the ABCG2 secretory uric acid transporter is very important in gut excretion (18), and PDZK1 is important in the correct localization of ABCG2 to the apical membrane in the gut (14, 36) . Urate is primarily generated in the liver from glycolysis and purine catabolic and recycling pathways (37). In the mouse, liver-specific knockout of SLC2A9 (that encodes GLUT9) results in hyperuricemia that results from blockage of the transport of urate into the liver for degradation by uricase (38). Humans have an inactive uricase and therefore substantially higher serum urate levels than mouse. Although SLC2A9 is expressed in the liver (39), the direction of hepatic transport of uric acid in humans is unknown. However, given that SLC2A9 has a typical PDZK1-binding PDZ motif (12) it is possible that increased hepatic expression of PDZK1 will stabilize SLC2A9 and thereby contribute to hyperuricemia, perhaps via increasing hepatic export of urate into the blood. Both the intestine and liver also express the transcriptional regulator HNF4A, and as outlined above, the urate-increasing T allele of PDZK1 rs1967017 is likely to have a stronger effect where HNF4A is expressed.
Further emphasizing the importance of HNF4A in urate control there is evidence that HNF4A is part of a transcriptional network regulating uric acid transporters (including GLUT9 (SLC2A9), OAT4 (SLC22A11), NPT1 (SLC17A1) and NPT4 (SLC17A3) (40,41)). Table 1 shows that while HNF4A is modestly expressed in the kidney cortex, its expression is higher in liver and intestine. Taken together, our results show that the urateincreasing allele of rs1967017 strengthens a strong HNF4A binding site close to the PDZK1 promoter, which is in turn likely to increase PDZK1 expression in cells that express HNF4A.
In summary, our results provide evidence for a mechanism for variant rs1967017 to affect serum urate via altered PDZK1 expression. It is likely that the urate-increasing variant increases transcription overall and effects PDZK1 levels through HNF4A.
MATERIALS AND METHODS
Imputation of the PDZK1 region
The summary level urate GWAS data were downloaded from:
http://metabolomics.helmholtz-muenchen.de/gugc/). Single nucleotide polymorphisms not present in the most recent 1000 Genomes release were removed, as were those where alleles were non-identical between the summary level data and 1000 Genomes. The effective sample size for each SNP was calculated using the Genome-wide Complex Trait Analysis (GCTA, v1.25.2) toolkit (42) and SNPs with effective sample sizes > 2 standard deviations from the mean were excluded. Finally, SNPs with a minor allele frequency (MAF) of less than 0.01 in the European population were excluded. ImpG (v1.0) (43) was used to impute z-scores into the summary statistics. For the reference haplotypes, the 1000 Genomes data set was used (44).
Vectors and constructs
An 857 bp DNA fragment (chr1:145,723,012-145,723,868) harboring rs1967017 was amplified from the genomic DNA of two individuals from the 1000 Genomes project (namely, HG00116 and HG00139) who were homozygous for the C and T alleles, respectively. Primers F: 5'-GGGCCACTAGGCTGTTCAT-3' and R: 5'-CAGGTCTGATTGTCCTAGTATGC-3' were used for amplification. Amplicons were cloned into pCR®8/GW/TOPO (Invitrogen) entry vector and gateway-cloned into the destination vectors pGL4.23-GW (Addgene 60323) (45) and pTol2Gata2 (46) using LR Clonase® enzyme (Invitrogen) for the enhancer assays in human cell lines and zebrafish expression assays, respectively. The vector construct used in the enhancer assay has previously been tested for different test enhancer regions that give a range of tissue-specific expression (47) -the GFP-expression pattern we observed was unique for the rs1967017-containing fragment.
In silico analysis of transcription factor binding sites
Transcription factor analysis on the 837 bp regulatory fragment was performed using three in silico tools. Using the 'Transcription Factor ChIP-Seq track' from ENCODE we analyzed our sequence for the presence of 161 transcription factors in 91 cell types. We found rs1967017 to alter the binding affinity of only the transcription factor HNF4A (MA0114.3) in the HepG2 cell line. The position weight matrix probabilities for the T and C alleles were 0.90 and 0.009 respectively. We confirmed the same finding using the HaploReg v4.1 tool (48), the PWM scores were 16.1 and 13 for the T and C allele respectively. In addition, we scanned our DNA sequence containing either the T allele or the C allele, using the JASPAR CORE 2018 database, which has a total of 719 transcription factor profiles (537 human and 182 rat/mouse), with a relative profile score threshold of 75%. The predicted binding scores for the C and the T alleles were 2.7 and 8.9 respectively. For the siRNA knockdown experiments, HepG2 cells were reverse-transfected with 10 nM scrambled control siRNA or 10 nM HNF4A siRNA (Dharmacon L-003406-00-0005)
Cell culture and transfections
using RNAiMax (Invitrogen), concurrently for gene expression analysis and for luciferase assay. After 24 hours, culture media was replaced with fresh MEM α and the cells were immediately transfected with luciferase reagents. Luminescence was measured 48 hours post-transfection and was normalized to Renilla.
Quantitative PCR
Total RNA was isolated from control siRNA-and HNF4A siRNA-treated HepG2 cells at 48 hours post-treatment using NucleoSpin RNA kit (Macherey-Nagel) and cDNA was synthesized with qScript cDNA SuperMix (Quanta Biosciences). HNF4A and PDZK1 expression was measured using SYBR Premix Ex Taq II (Takara) on the Roche LightCycler400. Primers used were HNF4A-F: 5'-GCGTGGTGGACAAAGACAAG-3', HNF4A-R: 5' AGCTTGACCTTCGAGTGCTG-3', PDZK1-F: 5'-AGCCCCGAATTGTGGAGATG-3' and PDZK1-R: 5'-TTTCCACAGACTCGCCGTTG-3'. Reference genes were GAPDH and PPIA.
Normalization was performed in qbase+.
Immunoblot analysis
Total protein was isolated from control siRNA-and HNF4A siRNA-treated HepG2 cells at 48 hours post-treatment by lysis in Radio-Immunoprecipitation Assay buffer containing protease inhibitor cocktail (Complete™, Roche 
Chromatin immunoprecipitation (ChIP)
The ChIP assay was performed as previously described (49) with minor modifications.
Briefly, chromatin was extracted from 10 million HepG2 cells and was sonicated (Vibra Cell VCX130 Sonicator, Sonics) to yield DNA fragments of ~500 bp, as determined experimentally. Lysates were diluted 1:10 with immunoprecipitation (IP) buffer. The diluted chromatin was pre-cleared overnight using Dynabeads protein G (Thermofisher).
Immunoprecipitation reactions were performed overnight at 4 °C using 10 μ l anti-HNF4A (ab41898, Abcam) antibody conjugated to 50 μ l of Dynabeads G.
DNA was recovered using Phenol:Chloroform:Isoamyl alcohol (Invitrogen) and precipitated with 0.1 volume of NaCl and 2.5 volumes of ethanol using Ambion Linear Acrylamide (5 mg/mL) as a carrier. qPCR was performed on 1 μ l of pre-cleared or For deep sequencing using the Illumina MiSeq, a two-step PCR approach was performed using the pre-cleared and immunoprecipitated chromatin as templates. In the first step, HNF4A motif primers modified to include an 18 bp adaptor-specific sequence were used to generate amplicons tagged at both ends by adaptor priming sites. The amplicons were purified using AMPure XP beads and were subjected to a second round of PCR using unique pairs of Illumina index primers. The indexed amplicons were purified using AMPure XP beads and quantified using the Qubit dsDNA HS Assay Kit. Amplicons were pooled to equal representation and 150 bp paired-end sequencing was performed.
Quality control, clean-up of reads and alignment to the human reference genome (GRCh37/hg19) were performed using a web-based open source platform, Galaxy.
Allelic frequencies were determined using the Integrative Genomics Viewer (50).
Zebrafish assays
Wild type (WIK), transgenic and mutant fish lines were maintained according to established protocols (51). Single-cell WIK embryos were injected with 1 nl of 30 ng/µl pTol2Gata2 (46) DNA construct containing either of the alleles and 90 ng/µl Tol2 transposase mRNA (52). Injected embryos were screened for enhancer expression under the Leica M205 FA epifluorescence microscope. Fluorescence-positive embryos were raised under standard conditions to F1 adults. These were outcrossed and the resulting embryos were imaged for fluorescence at 4 dpf using the Leica M205 FA epifluorescence microscope (Leica Applications Suite) and Nikon C2 confocal microscope (Nikon NIS-Elements).
Zebrafish histology
21 dpf larvae were fixed in 4% paraformaldehyde, embedded in paraffin and 3 micron sections were cut onto superfrost slides. Colorimetric in situ hybridization was carried out using a digoxigenin-labeled GFP riboprobe synthesized from a pCS2-EGFP plasmid using T7 RNA polymerase (Roche). Anti-DIG-alkaline phosphatase antibody (Roche) was used for detection, followed by visualization with nitro blue tetrazolium and 5bromo-4-chloro-3-indolylphosphate (NBT/BCIP) (Roche). Sections were imaged using brightfield microscopy on a Nikon CS2 microscope and Nikon NIS-Elements software.
Statistical analysis
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